The Hypertriglyceridemia Therapeutics Market Is Growing with Increasing Prevalence of Cardiovascular Diseases

Hypertriglyceridemia is an augmented level of triglycerides, a type of lipid, in the bloodstream, which are mainly related to cardiovascular diseases (CVDs), atherosclerosis, and other CVDs. The hypertriglyceridemia therapeutics market is gaining huge traction due to the advancements in terms of diagnosis and treatment of hypertriglyceridemia to rapidly recover triglyceride levels in the body. For instance, in December 2019, HLS Therapeutics announced that Health Canada has approved the use of Vascepa to reduce the risk of cardiovascular events in patients with elevated triglycerides and those who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, or at least one cardiovascular risk factor. Treatment of hypertriglyceridemia comprises diuretics, beta-blockers, estrogen therapy, and corticosteroids. The hypertriglyceridemia therapeutics market is expected to witness robust growth in North America, owing to increasing product launches ...